Innate Pharma SA
8.30%
7,825,501
1598599
45781K105
Dec 21, 2025
Feb 6, 2026, 09:48 AM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| AstraZeneca PLC | CO | 8.30% | 7,825,501 | 7,825,501 | 0 |
| MedImmune Limited | CO | 8.30% | 7,825,501 | 7,825,501 | 0 |
Disclosure Items (3)
Ordinary Shares, EUR0.05 nominal value per share
Innate Pharma SA
117 Avenue de Luminy, Marseille, I0, 13009
The current directors and executive officers of the Reporting Persons are set forth on Schedule I attached hereto.
AstraZeneca PLC: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. Percent of class: 8.3%. MedImmune Limited: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Percent of class: 8.3%. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. Percentage ownership calculated based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026.
See the information contained in Item 5(a), which is incorporated herein by reference.
Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Ordinary Shares, including Ordinary Shares represented by ADSs during the past 60 days.